Van ECK Associates Corp Has $186.95 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Van ECK Associates Corp lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2,567.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 352,217 shares of the medical research company’s stock after acquiring an additional 339,013 shares during the period. Van ECK Associates Corp’s holdings in Thermo Fisher Scientific were worth $186,954,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Sugarloaf Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton grew its holdings in Thermo Fisher Scientific by 3.7% during the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 19 shares during the period. Tsfg LLC grew its holdings in Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 19 shares during the period. Pacifica Partners Inc. grew its holdings in Thermo Fisher Scientific by 16.5% during the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after purchasing an additional 20 shares during the period. Finally, Retirement Planning Group LLC grew its holdings in Thermo Fisher Scientific by 4.9% during the fourth quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 21 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $3.27 on Monday, hitting $576.87. 962,347 shares of the stock were exchanged, compared to its average volume of 1,554,585. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The business’s fifty day moving average is $573.60 and its 200 day moving average is $530.40. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a market capitalization of $220.20 billion, a PE ratio of 36.82, a P/E/G ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold a total of 52,277 shares of company stock worth $29,649,264 over the last ninety days. Insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TMO. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Barclays upped their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, The Goldman Sachs Group upped their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.